Search

Your search keyword '"Montine, Thomas J"' showing total 1,479 results
Start Over Author "Montine, Thomas J" Language english
1,479 results on '"Montine, Thomas J"'

2. Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts

Author

Dam, Tien, Pagano, Gennaro, Brumm, Michael C., Gochanour, Caroline, Poston, Kathleen L., Weintraub, Daniel, Chahine, Lana M., Coffey, Christopher, Tanner, Caroline M., Kopil, Catherine M., Xiao, Yuge, Chowdhury, Sohini, Concha-Marambio, Luis, DiBiaso, Peter, Foroud, Tatiana, Frasier, Mark, Jennings, Danna, Kieburtz, Karl, Merchant, Kalpana, Mollenhauer, Brit, Montine, Thomas J., Nudelman, Kelly, Seibyl, John, Sherer, Todd, Singleton, Andrew, Stephenson, Diane, Stern, Matthew, Soto, Claudio, Tolosa, Eduardo, Siderowf, Andrew, Dunn, Billy, Simuni, Tanya, and Marek, Kenneth

Published
2024
Full Text
View/download PDF

3. Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort

Author

Phongpreecha, Thanaphong, Mathi, Kavita, Cholerton, Brenna, Fox, Eddie J., Sigal, Natalia, Espinosa, Camilo, Reincke, Momsen, Chung, Philip, Hwang, Ling-Jen, Gajera, Chandresh R., Berson, Eloise, Perna, Amalia, Xie, Feng, Shu, Chi-Hung, Hazra, Debapriya, Channappa, Divya, Dunn, Jeffrey E., Kipp, Lucas B., Poston, Kathleen L., Montine, Kathleen S., Maecker, Holden T., Aghaeepour, Nima, and Montine, Thomas J.

Published
2024
Full Text
View/download PDF

4. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease

Author

Rutledge, Jarod, Lehallier, Benoit, Zarifkar, Pardis, Losada, Patricia Moran, Shahid-Besanti, Marian, Western, Dan, Gorijala, Priyanka, Ryman, Sephira, Yutsis, Maya, Deutsch, Gayle K., Mormino, Elizabeth, Trelle, Alexandra, Wagner, Anthony D., Kerchner, Geoffrey A., Tian, Lu, Cruchaga, Carlos, Henderson, Victor W., Montine, Thomas J., Borghammer, Per, Wyss-Coray, Tony, and Poston, Kathleen L.

Published
2024
Full Text
View/download PDF

8. Mediterranean diet protects against a neuroinflammatory cortical transcriptome: Associations with brain volumetrics, peripheral inflammation, social isolation, and anxiety in nonhuman primates (Macaca fascicularis)

Author

Frye, Brett M., Negrey, Jacob D., Johnson, Corbin S.C., Kim, Jeongchul, Barcus, Richard A., Lockhart, Samuel N., Whitlow, Christopher T., Chiou, Kenneth L., Snyder-Mackler, Noah, Montine, Thomas J., Craft, Suzanne, Shively, Carol A., and Register, Thomas C.

Published
2024
Full Text
View/download PDF

10. Cross-species comparative analysis of single presynapses

Author

Berson, Eloïse, Gajera, Chandresh R., Phongpreecha, Thanaphong, Perna, Amalia, Bukhari, Syed A., Becker, Martin, Chang, Alan L., De Francesco, Davide, Espinosa, Camilo, Ravindra, Neal G., Postupna, Nadia, Latimer, Caitlin S., Shively, Carol A., Register, Thomas C., Craft, Suzanne, Montine, Kathleen S., Fox, Edward J., Keene, C. Dirk, Bendall, Sean C., Aghaeepour, Nima, and Montine, Thomas J.

Published
2023
Full Text
View/download PDF

11. Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature

Author

Berson, Eloise, Sreenivas, Anjali, Phongpreecha, Thanaphong, Perna, Amalia, Grandi, Fiorella C., Xue, Lei, Ravindra, Neal G., Payrovnaziri, Neelufar, Mataraso, Samson, Kim, Yeasul, Espinosa, Camilo, Chang, Alan L., Becker, Martin, Montine, Kathleen S., Fox, Edward J., Chang, Howard Y., Corces, M. Ryan, Aghaeepour, Nima, and Montine, Thomas J.

Published
2023
Full Text
View/download PDF

14. Clonal hematopoiesis is associated with protection from Alzheimer’s disease

Author

Bouzid, Hind, Belk, Julia A., Jan, Max, Qi, Yanyan, Sarnowski, Chloé, Wirth, Sara, Ma, Lisa, Chrostek, Matthew R., Ahmad, Herra, Nachun, Daniel, Yao, Winnie, Beiser, Alexa, Bick, Alexander G., Bis, Joshua C., Fornage, Myriam, Longstreth, Jr., William T., Lopez, Oscar L., Natarajan, Pradeep, Psaty, Bruce M., Satizabal, Claudia L., Weinstock, Joshua, Larson, Eric B., Crane, Paul K., Keene, C. Dirk, Seshadri, Sudha, Satpathy, Ansuman T., Montine, Thomas J., and Jaiswal, Siddhartha

Published
2023
Full Text
View/download PDF

15. Rapid Deployment of Whole Slide Imaging for Primary Diagnosis in Surgical Pathology at Stanford Medicine: Responding to Challenges of the COVID-19 Pandemic

Author

Rojansky, Rebecca, Jhun, Iny, Dussaq, Alex M., Chirieleison, Steven M., Nirschl, Jeffrey J., Born, Don, Fralick, Jennifer, Hetherington, William, Kerr, Alison M., Lavezo, Jonathan, Lawrence, Daniel B., Lummus, Seth, Macasaet, Ronald, Montine, Thomas J., Ryan, Emily, Shen, Jeanne, Shoemaker, Jonathan, Tan, Brent, Vogel, Hannes, Waraich, Puneet Singh, Yang, Eric, Young, April, and Folkins, Ann

Subjects
Diagnosis, Surgical -- Methods, Epidemics -- Control -- United States, Clinical pathology -- Methods, Immunohistochemistry -- Methods, Microscopy, Medical -- Methods, Medical laboratories -- Quality management, Health
Abstract

Context.--Stanford Pathology began stepwise subspecialty implementation of whole slide imaging (WSI) in 2018 soon after the first US Food and Drug Administration approval. In 2020, during the COVID-19 pandemic, the Centers for Medicare & Medicaid Services waived the requirement for pathologists to perform diagnostic tests in Clinical Laboratory Improvement Amendments (CLIA)-licensed facilities. This encouraged rapid implementation of WSI across all surgical pathology subspecialties. Objective.--To present our experience with validation and implementation of WSI at a large academic medical center encompassing a caseload of more than 50 000 cases per year. Design.--Validation was performed independently for 3 subspecialty services with a diagnostic concordance threshold above 95%. Analysis of user experience, staffing, infrastructure, and information technology was performed after department-wide expansion. Results.--Diagnostic concordance was achieved in 96% of neuropathology cases, 100% of gynecologic pathology cases, and 98% of immunohistochemistry cases. After full implementation, 8 high-capacity scanners were operational, with whole slide images generated on greater than 2000 slides per weekday, accounting for approximately 80% of histologic slides at Stanford Medicine. Multiple modifications in workflow and information technology were needed to improve performance. Within months of full implementation, most attending pathologists and trainees had adopted WSI for primary diagnosis. Conclusions.--WSI across all surgical subspecialities is achievable at scale at an academic medical center; however, adoption required flexibility to adjust workflows and develop tailored solutions. WSI at scale supported the health and safety of medical staff while facilitating high-quality patient care and education during COVID-19 restrictions. doi: 10.5858/arpa.2021-0438-OA, Whole slide imaging (WSI) for digital review of histologic slides in surgical pathology is a revolution in the practice of our craft and has significant operational, diagnostic, and research implications. [...]

Published
2023
Full Text
View/download PDF

16. LATE-NC staging in routine neuropathologic diagnosis: an update

Author

Nelson, Peter T., Lee, Edward B., Cykowski, Matthew D., Alafuzoff, Irina, Arfanakis, Konstantinos, Attems, Johannes, Brayne, Carol, Corrada, Maria M., Dugger, Brittany N., Flanagan, Margaret E., Ghetti, Bernardino, Grinberg, Lea T., Grossman, Murray, Grothe, Michel J., Halliday, Glenda M., Hasegawa, Masato, Hokkanen, Suvi R. K., Hunter, Sally, Jellinger, Kurt, Kawas, Claudia H., Keene, C. Dirk, Kouri, Naomi, Kovacs, Gabor G., Leverenz, James B., Latimer, Caitlin S., Mackenzie, Ian R., Mao, Qinwen, McAleese, Kirsty E., Merrick, Richard, Montine, Thomas J., Murray, Melissa E., Myllykangas, Liisa, Nag, Sukriti, Neltner, Janna H., Newell, Kathy L., Rissman, Robert A., Saito, Yuko, Sajjadi, S. Ahmad, Schwetye, Katherine E., Teich, Andrew F., Thal, Dietmar R., Tomé, Sandra O., Troncoso, Juan C., Wang, Shih-Hsiu J., White, III, Charles L., Wisniewski, Thomas, Yang, Hyun-Sik, Schneider, Julie A., Dickson, Dennis W., and Neumann, Manuela

Published
2023
Full Text
View/download PDF

18. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts

Author

Nelson, Peter T., Brayne, Carol, Flanagan, Margaret E., Abner, Erin L., Agrawal, Sonal, Attems, Johannes, Castellani, Rudolph J., Corrada, Maria M., Cykowski, Matthew D., Di, Jing, Dickson, Dennis W., Dugger, Brittany N., Ervin, John F., Fleming, Jane, Graff-Radford, Jonathan, Grinberg, Lea T., Hokkanen, Suvi R. K., Hunter, Sally, Kapasi, Alifiya, Kawas, Claudia H., Keage, Hannah A. D., Keene, C. Dirk, Kero, Mia, Knopman, David S., Kouri, Naomi, Kovacs, Gabor G., Labuzan, Sydney A., Larson, Eric B., Latimer, Caitlin S., Leite, Renata E. P., Matchett, Billie J., Matthews, Fiona E., Merrick, Richard, Montine, Thomas J., Murray, Melissa E., Myllykangas, Liisa, Nag, Sukriti, Nelson, Ruth S., Neltner, Janna H., Nguyen, Aivi T., Petersen, Ronald C., Polvikoski, Tuomo, Reichard, R. Ross, Rodriguez, Roberta D., Suemoto, Claudia K., Wang, Shih-Hsiu J., Wharton, Stephen B., White, Lon, and Schneider, Julie A.

Published
2022
Full Text
View/download PDF

22. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease

Author

Wilson, Edward N., Young, Christina B., Ramos Benitez, Javier, Swarovski, Michelle S., Feinstein, Igor, Vandijck, Manu, Le Guen, Yann, Kasireddy, Nandita M., Shahid, Marian, Corso, Nicole K., Wang, Qian, Kennedy, Gabriel, Trelle, Alexandra N., Lind, Betty, Channappa, Divya, Belnap, Malia, Ramirez, Veronica, Skylar-Scott, Irina, Younes, Kyan, Yutsis, Maya V., Le Bastard, Nathalie, Quinn, Joseph F., van Dyck, Christopher H., Nairn, Angus, Fredericks, Carolyn A., Tian, Lu, Kerchner, Geoffrey A., Montine, Thomas J., Sha, Sharon J., Davidzon, Guido, Henderson, Victor W., Longo, Frank M., Greicius, Michael D., Wagner, Anthony D., Wyss-Coray, Tony, Poston, Kathleen L., Mormino, Elizabeth C., and Andreasson, Katrin I.

Published
2022
Full Text
View/download PDF

23. Single-cell spatial proteomic imaging for human neuropathology

Author

Vijayaragavan, Kausalia, Cannon, Bryan J., Tebaykin, Dmitry, Bossé, Marc, Baranski, Alex, Oliveria, J. P., Bukhari, Syed A., Mrdjen, Dunja, Corces, M. Ryan, McCaffrey, Erin F., Greenwald, Noah F., Sigal, Yari, Marquez, Diana, Khair, Zumana, Bruce, Trevor, Goldston, Mako, Bharadwaj, Anusha, Montine, Kathleen S., Angelo, R. Michael, Montine, Thomas J., and Bendall, Sean C.

Published
2022
Full Text
View/download PDF

25. Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.

Author

Abdelnour, Carla, Young, Christina B., Shahid‐Besanti, Marian, Smith, Alena, Wilson, Edward N., Ramos Benitez, Javier, Vossler, Hillary, Plastini, Melanie J., Winer, Joseph R., Kerchner, Geoffrey A., Cholerton, Brenna, Andreasson, Katrin I., Henderson, Victor W., Yutsis, Maya, Montine, Thomas J., Tian, Lu, Mormino, Elizabeth C., and Poston, Kathleen L.

Subjects
RECEIVER operating characteristic curves, ALZHEIMER'S disease, COGNITION disorders, DISEASE progression, AMYLOIDOSIS
Abstract

Objective: To determine whether plasma phosphorylated‐Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and susceptibility/risk biomarker for clinical outcomes in Lewy body disease (LBD). Methods: We studied 565 participants: 94 LBD with normal cognition, 83 LBD with abnormal cognition, 114 with Alzheimer's disease, and 274 cognitively normal. Plasma pTau181 levels were measured with the Lumipulse G platform. Diagnostic accuracy for concurrent ADNC and amyloidosis was assessed with Receiver Operating Characteristic curves in a subset of participants with CSF pTau181/Aβ42, and CSF Aβ42/Aβ40 or amyloid‐β PET, respectively. Linear mixed effects models were used to examine the associations between baseline and longitudinal plasma pTau181 levels and clinical outcomes. Results: Plasma pTau181 predicted concurrent ADNC and amyloidosis in LBD with abnormal cognition with 87% and 72% accuracy, respectively. In LBD patients with abnormal cognition, higher baseline plasma pTau181 was associated with worse baseline MoCA and CDR‐SB, as well as accelerated decline in CDR‐SB. Additionally, in this group, rapid increases in plasma pTau181 over 3 years predicted a faster decline in CDR‐SB and memory. In LBD patients with normal cognition, there was no association between baseline or longitudinal plasma pTau181 levels and clinical outcomes; however, elevated pTau181 at baseline increased the risk of conversion to cognitive impairment. Interpretation: Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024;96:526–538 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Genome-wide association study and functional validation implicates JADE1 in tauopathy

Author

Farrell, Kurt, Kim, SoongHo, Han, Natalia, Iida, Megan A., Gonzalez, Elias M., Otero-Garcia, Marcos, Walker, Jamie M., Richardson, Timothy E., Renton, Alan E., Andrews, Shea J., Fulton-Howard, Brian, Humphrey, Jack, Vialle, Ricardo A., Bowles, Kathryn R., de Paiva Lopes, Katia, Whitney, Kristen, Dangoor, Diana K., Walsh, Hadley, Marcora, Edoardo, Hefti, Marco M., Casella, Alicia, Sissoko, Cheick T., Kapoor, Manav, Novikova, Gloriia, Udine, Evan, Wong, Garrett, Tang, Weijing, Bhangale, Tushar, Hunkapiller, Julie, Ayalon, Gai, Graham, Robert R., Cherry, Jonathan D., Cortes, Etty P., Borukov, Valeriy Y., McKee, Ann C., Stein, Thor D., Vonsattel, Jean-Paul, Teich, Andy F., Gearing, Marla, Glass, Jonathan, Troncoso, Juan C., Frosch, Matthew P., Hyman, Bradley T., Dickson, Dennis W., Murray, Melissa E., Attems, Johannes, Flanagan, Margaret E., Mao, Qinwen, Mesulam, M.-Marsel, Weintraub, Sandra, Woltjer, Randy L., Pham, Thao, Kofler, Julia, Schneider, Julie A., Yu, Lei, Purohit, Dushyant P., Haroutunian, Vahram, Hof, Patrick R., Gandy, Sam, Sano, Mary, Beach, Thomas G., Poon, Wayne, Kawas, Claudia H., Corrada, María M., Rissman, Robert A., Metcalf, Jeff, Shuldberg, Sara, Salehi, Bahar, Nelson, Peter T., Trojanowski, John Q., Lee, Edward B., Wolk, David A., McMillan, Corey T., Keene, C. Dirk, Latimer, Caitlin S., Montine, Thomas J., Kovacs, Gabor G., Lutz, Mirjam I., Fischer, Peter, Perrin, Richard J., Cairns, Nigel J., Franklin, Erin E., Cohen, Herbert T., Raj, Towfique, Cobos, Inma, Frost, Bess, Goate, Alison, White III, Charles L., and Crary, John F.

Published
2022
Full Text
View/download PDF

29. Neuropathologic changes at age 90+ related to sleep duration 19 to 40 years earlier: The 90+ Study.

Author

Melikyan, Zarui A., Kawas, Claudia H., Paganini‐Hill, Annlia, Jiang, Luohua, Bukhari, Syed, Montine, Thomas J., Mander, Bryce A., and Corrada, María M.

Abstract

INTRODUCTION: We investigated the association between sleep duration and neuropathologic changes 19 to 40 years later in oldest‐old (age 90+) participants of The 90+ Study. METHODS: Participants self‐reported sleep duration and underwent neuropathologic evaluation. We categorized sleep duration as < 7, 7 to 8 = reference, > 8 hours and dichotomized neuropathologic changes as present/absent. We estimated odds ratio (OR) and 95% confidence intervals (CI) using logistic regression. RESULTS: In 264 participants, mean age at sleep self‐report was 69 years, mean age at autopsy was 98 years, and mean interval between sleep self‐report and autopsy was 29 years (range: 19–40). Those reporting > 8 hours of sleep had lower likelihood of limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC) inclusions (OR = 0.18; CI = 0.04–0.82) and amyloid beta deposits (OR = 0.34; 95% CI = 0.12–0.94). DISCUSSION: Long self‐reported sleep is associated with lower odds of neurodegenerative neuropathologic changes 19 to 40 years later in the oldest‐old, suggesting a potential role of sleep in accumulation of dementia‐related neuropathologies. Highlights: Association of self‐reported sleep with non‐Alzheimer's disease neuropathologic changes has not been explored.Whether sleep duration is related to dementia neuropathologic changes decades later is unclear.Long self‐reported sleep is associated with lower odds of Alzheimer's disease neuropathologic change 19 to 40 years later in the oldest‐old.Long self‐reported sleep is associated with lower odds of limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change 19 to 40 years later in the oldest‐old. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.

Author

Plastini, Melanie J., Abdelnour, Carla, Young, Christina B., Wilson, Edward N., Shahid‐Besanti, Marian, Lamoureux, Jennifer, Andreasson, Katrin I., Kerchner, Geoffrey A., Montine, Thomas J., Henderson, Victor W., and Poston, Kathleen L.

Subjects
ALZHEIMER'S disease, BIOMARKERS, RECEIVER operating characteristic curves, NEURODEGENERATION, ALPHA-synuclein
Abstract

Objective: More than half of neurodegenerative disease patients have multiple pathologies at autopsy; however, most receive one diagnosis during life. We used the α‐synuclein seed amplification assay (αSyn‐SAA) and CSF biomarkers for amyloidosis and Alzheimer's disease (AD) neuropathological change (ADNC) to determine the frequency of co‐pathologies in participants clinically diagnosed with Lewy body (LB) disease or AD. Methods: Using receiver operating characteristic analyses on retrospective CSF samples from 150 participants determined αSyn‐SAA accuracy, sensitivity, and specificity for identifying clinically defined LB disease and predicting future change in clinical diagnosis. CSF biomarkers helped determine the frequency of concomitant Lewy body pathology, ADNC, and/or amyloidosis in participants with LB disease and AD, across clinical spectra. Results: Following a decade‐long follow‐up, the clinically or autopsy‐defined diagnosis changed for nine participants. αSyn‐SAA demonstrated improved accuracy (91.3%), sensitivity (89.3%), and specificity (93.3%) for identifying LB disease compared to all non‐LB disease, highlighting the limitations of clinical diagnosis alone. When examining biomarkers of co‐pathology, amyloidosis was present in 18%, 48%, and 71% (χ2(2) = 13.56, p = 0.001) and AD biomarkers were present in 0%, 8.7%, and 42.9% (χ2(2) = 18.44, p < 0.001) of LB disease participants with different stages of cognitive impairment respectively. Co‐occurring biomarkers for αSyn‐SAA and amyloidosis were present in 12% and 14% of AD compared to 43% and 57% LB disease participants with different stages of cognitive impairment (χ2(3) = 13.87, p = 0.003). Interpretation: Our study shows that using a combination of αSyn‐SAA and AD biomarkers can identify people with αSyn, ADNC, and co‐pathology better and earlier than traditional clinical diagnostic criteria alone. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer’s and Parkinson’s diseases

Author

Corces, M. Ryan, Shcherbina, Anna, Kundu, Soumya, Gloudemans, Michael J., Frésard, Laure, Granja, Jeffrey M., Louie, Bryan H., Eulalio, Tiffany, Shams, Shadi, Bagdatli, S. Tansu, Mumbach, Maxwell R., Liu, Boxiang, Montine, Kathleen S., Greenleaf, William J., Kundaje, Anshul, Montgomery, Stephen B., Chang, Howard Y., and Montine, Thomas J.

Published
2020
Full Text
View/download PDF

35. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

Author

Johnson, Erik C. B., Dammer, Eric B., Duong, Duc M., Ping, Lingyan, Zhou, Maotian, Yin, Luming, Higginbotham, Lenora A., Guajardo, Andrew, White, Bartholomew, Troncoso, Juan C., Thambisetty, Madhav, Montine, Thomas J., Lee, Edward B., Trojanowski, John Q., Beach, Thomas G., Reiman, Eric M., Haroutunian, Vahram, Wang, Minghui, Schadt, Eric, Zhang, Bin, Dickson, Dennis W., Ertekin-Taner, Nilüfer, Golde, Todd E., Petyuk, Vladislav A., De Jager, Philip L., Bennett, David A., Wingo, Thomas S., Rangaraju, Srikant, Hajjar, Ihab, Shulman, Joshua M., Lah, James J., Levey, Allan I., and Seyfried, Nicholas T.

Published
2020
Full Text
View/download PDF

39. Lewy body dementia: Overcoming barriers and identifying solutions.

Author

Agarwal, Kanishka, Backler, Wendi, Bayram, Ece, Bloom, Leah, Boeve, Bradley F., Cha, Jang‐Ho, Denslow, Maria, Ferman, Tanis J., Galasko, Douglas, Galvin, James E., Gomperts, Stephen N., Irizarry, Michael C., Kantarci, Kejal, Kaushik, Harsh, Kietlinski, Matt, Koenig, Aaron, Leverenz, James B., McKeith, Ian, McLean, Pamela J., and Montine, Thomas J.

Abstract

Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public‐health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public‐domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor. Highlights: A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research.Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

Author

Knopman, David S., Haeberlein, Samantha Budd, Carrillo, Maria C., Hendrix, James A., Kerchner, Geoff, Margolin, Richard, Maruff, Paul, Miller, David S., Tong, Gary, Tome, Maria B., Murray, Melissa E., Nelson, Peter T., Sano, Mary, Mattsson, Niklas, Sultzer, David L., Montine, Thomas J., Jack, Clifford R., Jr., Kolb, Hartmuth, Petersen, Ronald C., Vemuri, Prashanthi, Canniere, Megan Zoschg, Schneider, Julie A., Resnick, Susan M., Romano, Gary, van Harten, Argonde Corien, Wolk, David A., Bain, Lisa J., and Siemers, Eric

Published
2018
Full Text
View/download PDF

42. Sex-specific genetic predictors of Alzheimer’s disease biomarkers

Author

Deming, Yuetiva, Dumitrescu, Logan, Barnes, Lisa L., Thambisetty, Madhav, Kunkle, Brian, Gifford, Katherine A., Bush, William S., Chibnik, Lori B., Mukherjee, Shubhabrata, De Jager, Philip L., Kukull, Walter, Huentelman, Matt, Crane, Paul K., Resnick, Susan M., Keene, C. Dirk, Montine, Thomas J., Schellenberg, Gerard D., Haines, Jonathan L., Zetterberg, Henrik, Blennow, Kaj, Larson, Eric B., Johnson, Sterling C., Albert, Marilyn, Moghekar, Abhay, del Aguila, Jorge L., Fernandez, Maria Victoria, Budde, John, Hassenstab, Jason, Fagan, Anne M., Riemenschneider, Matthias, Petersen, Ronald C., Minthon, Lennart, Chao, Michael J., Van Deerlin, Vivianna M., Lee, Virginia M.-Y., Shaw, Leslie M., Trojanowski, John Q., Peskind, Elaine R., Li, Gail, Davis, Lea K., Sealock, Julia M., Cox, Nancy J., Alzheimer’s Disease Neuroimaging Initiative (ADNI), The Alzheimer Disease Genetics Consortium (ADGC), Goate, Alison M., Bennett, David A., Schneider, Julie A., Jefferson, Angela L., Cruchaga, Carlos, and Hohman, Timothy J.

Published
2018
Full Text
View/download PDF

43. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Author

Ringman, John M, Frautschy, Sally A, Teng, Edmond, Begum, Aynun N, Bardens, Jenny, Beigi, Maryam, Gylys, Karen H, Badmaev, Vladimir, Heath, Dennis D, Apostolova, Liana G, Porter, Verna, Vanek, Zeba, Marshall, Gad A, Hellemann, Gerhard, Sugar, Catherine, Masterman, Donna L, Montine, Thomas J, Cummings, Jeffrey L, and Cole, Greg M

Abstract

Abstract Introduction Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidate for treating human AD. The purpose of the current study is to generate tolerability and preliminary clinical and biomarker efficacy data on curcumin in persons with AD. Methods We performed a 24-week randomized, double blind, placebo-controlled study of Curcumin C3 Complex® with an open-label extension to 48 weeks. Thirty-six persons with mild-to-moderate AD were randomized to receive placebo, 2 grams/day, or 4 grams/day of oral curcumin for 24 weeks. For weeks 24 through 48, subjects that were receiving curcumin continued with the same dose, while subjects previously receiving placebo were randomized in a 1:1 ratio to 2 grams/day or 4 grams/day. The primary outcome measures were incidence of adverse events, changes in clinical laboratory tests and the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at 24 weeks in those completing the study. Secondary outcome measures included the Neuropsychiatric Inventory (NPI), the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale, levels of Aβ1-40 and Aβ1-42 in plasma and levels of Aβ1-42, t-tau, p-tau181 and F2-isoprostanes in cerebrospinal fluid. Plasma levels of curcumin and its metabolites up to four hours after drug administration were also measured. Results Mean age of completers (n = 30) was 73.5 years and mean Mini-Mental Status Examination (MMSE) score was 22.5. One subject withdrew in the placebo (8%, worsened memory) and 5/24 subjects withdrew in the curcumin group (21%, 3 due to gastrointestinal symptoms). Curcumin C3 Complex® was associated with lowered hematocrit and increased glucose levels that were clinically insignificant. There were no differences between treatment groups in clinical or biomarker efficacy measures. The levels of native curcumin measured in plasma were low (7.32 ng/mL). Conclusions Curcumin was generally well-tolerated although three subjects on curcumin withdrew due to gastrointestinal symptoms. We were unable to demonstrate clinical or biochemical evidence of efficacy of Curcumin C3 Complex® in AD in this 24-week placebo-controlled trial although preliminary data suggest limited bioavailability of this compound. Trial registration ClinicalTrials.gov Identifier: NCT00099710.

Published
2012

47. Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and Caenorhabditis elegans experiments

Author

Mukherjee, Shubhabrata, Russell, Joshua C., Carr, Daniel T., Burgess, Jeremy D., Allen, Mariet, Serie, Daniel J., Boehme, Kevin L., Kauwe, John S.K., Naj, Adam C., Fardo, David W., Dickson, Dennis W., Montine, Thomas J., Ertekin-Taner, Nilufer, Kaeberlein, Matt R., and Crane, Paul K.

Published
2017
Full Text
View/download PDF

48. Transethnic genome-wide scan identifies novel Alzheimer's disease loci

Author

Adams, Perrie M., Albert, Marilyn S., Albin, Roger L., Apostolova, Liana G., Arnold, Steven E., Asthana, Sanjay, Atwood, Craig S., Barmada, Michjael M., Barnes, Lisa L., Beach, Thomas G., Becker, James T., Bigio, Eileen H., Bird, Thomas D., Blacker, Deborah, Boeve, Bradley F., Bowen, James D., Boxer, Adam, Burke, James R., Cairns, Nigel J., Cao, Chuanhai, Carlson, Chris S., Carlsson, Cynthia M., Carney, Regina M., Carrasquillo, Minerva M., Carroll, Steven L., Chui, Helena C., Clark, David G., Corneveaux, Jason, Cribbs, David H., Crocco, Elizabeth A., Cruchaga, Carlos, De Jager, Philip L., DeCarli, Charles, DeKosky, Steven T., Demirci, F. Yesim, Dick, Malcolm, Dickson, Dennis W., Doody, Rachelle S., Duara, Ranjan, Ertekin-Taner, Nilufer, Faber, Kelley M., Fairchild, Thomas J., Fallon, Kenneth B., Farlow, Martin R., Ferris, Steven, Frosch, Matthew P., Galasko, Douglas R., Gearing, Marla, Geschwind, Daniel H., Ghetti, Bernardino, Gilbert, John R., Glass, Jonathan D., Graff-Radford, Neill R., Green, Robert C., Growdon, John H., Hakonarson, Hakon, Hamilton, Ronald L., Hardy, John, Harrell, Lindy E., Head, Elizabeth, Honig, Lawrence S., Huebinger, Ryan M., Huentelman, Matthew J., Hulette, Christine M., Hyman, Bradley T., Jarvik, Gail P., Jicha, Gregory A., Jin, Lee-Way, Karydas, Anna, Kauwe, John S.K., Kaye, Jeffrey A., Kim, Ronald, Koo, Edward H., Kowall, Neil W., Kramer, Joel H., LaFerla, Frank M., Lah, James J., Leverenz, James B., Levey, Allan I., Li, Ge, Lieberman, Andrew P., Lin, Chiao-Feng, Lopez, Oscar L., Lyketsos, Constantine G., Mack, Wendy J., Marson, Daniel C., Martiniuk, Frank, Mash, Deborah C., Masliah, Eliezer, McCormick, Wayne C., McCurry, Susan M., McDavid, Andrew N., McKee, Ann C., Mesulam, Marsel, Miller, Bruce L., Miller, Carol A., Miller, Joshua W., Morris, John C., Mukherjee, Shubhabrata, Murrell, Jill R., Myers, Amanda J., O'Bryant, Sid, Olichney, John M., Pankratz, Vernon S., Parisi, Joseph E., Partch, Amanda, Paulson, Henry L., Perry, William, Peskind, Elaine, Petersen, Ronald C., Pierce, Aimee, Poon, Wayne W., Potter, Huntington, Quinn, Joseph F., Raj, Ashok, Raskind, Murray, Reisberg, Barry, Reisch, Joan S., Reitz, Christiane, Ringman, John M., Roberson, Erik D., Rogaeva, Ekaterina, Rosen, Howard J., Rosenberg, Roger N., Royall, Donald R., Sager, Mark A., Sano, Mary, Saykin, Andrew J., Schneider, Julie A., Schneider, Lon S., Seeley, William W., Smith, Amanda G., Sonnen, Joshua A., Spina, Salvatore, Stern, Robert A., Tanzi, Rudolph E., Thornton-Wells, Tricia A., Trojanowski, John Q., Troncoso, Juan C., Tsuang, Debby W., Van Deerlin, Vivianna M., Van Eldik, Linda J., Vardarajan, Badri N., Vinters, Harry V., Vonsattel, Jean Paul, Weintraub, Sandra, Welsh-Bohmer, Kathleen A., Williamson, Jennifer, Wishnek, Sarah, Woltjer, Randall L., Wright, Clinton B., Wu, Chuang-Kuo, Yu, Chang-En, Yu, Lei, Zhang, Xiaoling, Jun, Gyungah R., Chung, Jaeyoon, Mez, Jesse, Barber, Robert, Beecham, Gary W., Bennett, David A., Buxbaum, Joseph D., Byrd, Goldie S., Crane, Paul K., De Jager, Philip, Evans, Denis, Fallin, M. Danielle, Foroud, Tatiana M., Friedland, Robert P., Goate, Alison M., Hendrie, Hugh, Hall, Kathleen S., Hamilton-Nelson, Kara L., Inzelberg, Rivka, Kamboh, M. Ilyas, Kukull, Walter A., Kunkle, Brian W., Kuwano, Ryozo, Larson, Eric B., Logue, Mark W., Manly, Jennifer J., Martin, Eden R., Montine, Thomas J., Naj, Adam, Reiman, Eric M., Sherva, Richard, St. George-Hyslop, Peter H., Thornton, Timothy, Younkin, Steven G., Wang, Li-San, Wendlund, Jens R., Winslow, Ashley R., Haines, Jonathan, Mayeux, Richard, Pericak-Vance, Margaret A., Schellenberg, Gerard, Lunetta, Kathryn L., and Farrer, Lindsay A.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results